459 related articles for article (PubMed ID: 29909916)
1. Toxicities associated with immunotherapies for hematologic malignancies.
Leick MB; Maus MV
Best Pract Res Clin Haematol; 2018 Jun; 31(2):158-165. PubMed ID: 29909916
[TBL] [Abstract][Full Text] [Related]
2. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
3. Off the shelf T cell therapies for hematologic malignancies.
McCreedy BJ; Senyukov VV; Nguyen KT
Best Pract Res Clin Haematol; 2018 Jun; 31(2):166-175. PubMed ID: 29909917
[TBL] [Abstract][Full Text] [Related]
4. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
Holstein SA; Lunning MA
Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
[TBL] [Abstract][Full Text] [Related]
5. Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.
Murad JM; Graber DJ; Sentman CL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):176-183. PubMed ID: 29909918
[TBL] [Abstract][Full Text] [Related]
6. CAR T cells, immunologic and cellular therapies in hematologic malignancies.
Brentjens R; Davila ML
Best Pract Res Clin Haematol; 2018 Jun; 31(2):115-116. PubMed ID: 29909911
[No Abstract] [Full Text] [Related]
7. CAR T-cell therapy: perceived need versus actual evidence.
The Lancet Oncology
Lancet Oncol; 2018 Oct; 19(10):1259. PubMed ID: 30303110
[No Abstract] [Full Text] [Related]
8. State of the art in CAR T cell therapy for CD19+ B cell malignancies.
Frigault MJ; Maus MV
J Clin Invest; 2020 Apr; 130(4):1586-1594. PubMed ID: 32235098
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B
Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Advances in Immunotherapies for Hematological Malignancies.
Nogami A; Sasaki K
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232824
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell therapy for haematological malignancies.
Selim AG; Tam CS
Med J Aust; 2020 Nov; 213(9):404-406.e1. PubMed ID: 32951222
[No Abstract] [Full Text] [Related]
12. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
[TBL] [Abstract][Full Text] [Related]
13. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
Front Immunol; 2021; 12():670286. PubMed ID: 34135898
[TBL] [Abstract][Full Text] [Related]
14. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
Hill JA; Seo SK
Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
[TBL] [Abstract][Full Text] [Related]
15. CAR T Cell Therapy for Hematological Malignancies.
Yang X; Wang GX; Zhou JF
Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
[TBL] [Abstract][Full Text] [Related]
16. Practical aspects of building a new immunotherapy program: the future of cell therapy.
Berdeja JG
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):579-584. PubMed ID: 33275680
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Rubio MT; Galaine J; Borg C; Daguindau É
Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
[TBL] [Abstract][Full Text] [Related]
18. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety.
Halim L; Ajina A; Maher J
Best Pract Res Clin Haematol; 2018 Jun; 31(2):117-125. PubMed ID: 29909912
[TBL] [Abstract][Full Text] [Related]
20. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
Wang W; Jiang J; Wu C
Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
